edoc

Items where Author is "Medinger, M."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed
Jump to: 2017 | 2013 | 2012 | 2011 | 2008 | 2005 | 2004 | 2003 | 2002
Number of items: 10.

2017

Tichelli, A. and Gerull, S. and Holbro, A. and Buser, A. and Nair, G. and Medinger, M. and Heim, D. and Halter, J. P. and Passweg, J. R.. (2017) Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplantation, 52 (10). pp. 1436-1442.

2013

Medinger, M. and Tichelli, A. and Bucher, C. and Halter, J. and Dirnhofer, S. and Rovo, A. and Passweg, J. and Tzankov, A.. (2013) GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM. Bone Marrow Transplantation, 48 (5). pp. 715-721.

2012

Gavillet, M. and Medinger, M. and Tichelli, A. and Fux-Arnold, C.. (2012) Neutropenia and fever of unknown origin. PRAXIS, 101 (24). pp. 1573-1576.

2011

Medinger, M. and Esser, N. and Soltau, J. and Lehmann, K. M. and Konerding, M. A. and Wolloscheck, T. and Ryan, A. J. and Drevs, J.. (2011) Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model. International journal of oncology, 38 (2). pp. 455-464.

2008

Buser, A. and Stern, M. and Arber, C. and Medinger, M. and Halter, J. and Rovo, A. and Favre, G. and Lohri, A. and Tichelli, A. and Gratwohl, A.. (2008) Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab? Bone Marrow Transplantation, 42 (7). pp. 483-487.

Rovó, A. and Daikeler, T. and Stern, M. and Halter, J. and Studt, J. D. and Buser, A. and Heim, D. and Rischewski, J. and Medinger, M. and Tyndall, A. and Gratwohl, A. and Tichelli, A.. (2008) Physical and not mental health is impaired in very long-term survivors after HSCT compared with their respective donors: a paired analysis. Blood, 111. pp. 1740-1741.

2005

Drevs, J. and Zirrgiebel, U. and Schmidt-Gersbach, C. I. M. and Mross, K. and Medinger, M. and Lee, L. and Pinheiro, J. and Wood, J. and Thomas, A. L. and Unger, C. and Henry, A. and Steward, W. P. and Laurent, D. and Lebwohl, D. and Dugan, M. and Marmé, D.. (2005) Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Annals of Oncology, 16 (4). pp. 558-565.

2004

Medinger, M. and Steinbild, S. and Mross, K.. (2004) Adjuvant and palliative anticancer treatment of colon carcinoma in 2004. PRAXIS, 93 (40). pp. 1633-1644.

2003

Medinger, M. and Adler, C. P. and Schmidt-Gersbach, C. and Soltau, J. and Droll, A. and Unger, C. and Drevs, J.. (2003) Angiogenesis and the ET-1/ETA receptor system: immunohistochemical expression analysis in bone metastases from patients with different primary tumors. Angiogenesis, 6 (3). pp. 225-231.

2002

Drevs, J. and Laus, C. and Medinger, M. and Schmidt-Gersbach, C. and Unger, C.. (2002) Antiangiogenesis: current clinical data and future perspectives. Onkologie, 25 (6). pp. 520-527.

This list was generated on Sat Apr 20 16:53:10 2024 CEST.